Article Details

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

Retrieved on: 2023-12-04 16:06:52

Tags for this article:

Click the tags to see associated articles and topics

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia. View article details on hiswai:

Excerpt

GT Biopharma, Inc. announced the submission of an Investigational New Drug application with the US Food and Drug Administration for the ...

Article found on: www.marketscreener.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up